Alzheimer's disease neuroimaging initiative

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Project Description:
Overall: Project Summary/Abstract The overall goal of the Alzheimer's Disease (AD) Neuroimaging Initiative (ADNI) is to discover, standardize, and validate biomarkers for AD treatment trials. Validation is accomplished by comparing and correlating clinical/cognitive with biomarker data. Impact of ADNI has been to optimize, standardize and validate biomarkers, especially brain amyloid by PET and CSF measurements of A? peptides, termed ?A? amyloid- phenotyping.? There are 907 papers published using ADNI data. We will follow-up with annual visits, 697 subjects previously enrolled in ADNI2 (cognitively normal controls, subjects currently enrolled subjects with MCI, and patients with dementia diagnosed as AD) and will enroll 371 new subjects, while collecting clinical, cognitive, MRI (structural, diffusion, perfusion, resting state), amyloid PET, FDG PET, cerebrospinal fluid (for a A?, tau, phosphotau, and other proteins), genetic and autopsy data. In addition longitudinal measurements of brain tau PET will be performed on all subjects. All data is available without embargo to from USC/LONI/ADNI. Specific Aims: 1. Longitudinal changes in cognition and associated biomarkers: To determine those measures of cognition and function, including composite measures, and those biomarker measures which best capture longitudinal change with highest statistical power to detect treatment effects in clinical trials. Longitudinal change of brain tau tangles measured with tau PET will be correlated/compared with other measures. 2. Prediction of cognitive decline: To determine the clinical, cognitive, and biomarker measures which best predict decline of cognition in cognitively normal controls, subjects with MCI, and patients with dementia. In addition, to determine those biomarkers, especially tau PET, which correlate with cognitive decline. 3. Validation: To validate biomarker measures obtained at baseline and longitudinally by correlating results with ?gold standard? clinical measurements and pathology. 4. Clinical trial design: To determine the optimum outcome measures (especially rate of cognitive decline and tau PET), predictors of cognitive decline, and inclusion/exclusion criteria for clinical trials of cognitively normal subjects (for secondary preclinical AD trials) and MCI patients (for prodromal AD trials). 5. Discovery: To determine the effects of other known disease proteins found in AD brains (e.g. alpha- synuclein, TDP 43,progranulin) and genes, and newly discovered proteins (from proteinomics), genes,and other analytes (from metabolomics) which provide useful information concerning the pathogenesis/diagnosis of AD. Discovery is conducted through the add-on studies led/driven by ADNI investigators with oversight by the NIA and the ADNI Resource Allocation Review Committee (RARC). ADNI methods and data are used in study design by government and industry funded clinical trials. Continuation of ADNI will help lead to development of effective treatments which slow progression and prevent AD.
 
Project Terms:
alpha synuclein alzheimer disease prevention alzheimer's disease american amyloid amyloid beta-protein autopsy biological markers biomarker discovery blood tests brain brain diseases brain imaging cerebrospinal fluid clinical clinical assessments clinical diagnosis clinical treatment clinical trials clinical trials design cognition cognitive cognitive testing communities controlled clinical trials cost data dementia deposition design development diagnosis diagnostic diagnostic accuracy diagnostic procedure diffusion disease disease progression disorder prevention drug industry effective therapy emotions enrollment exclusion criteria family support follow-up foundations funding genes genetic goals gold government impaired cognition industry lead magnetic resonance imaging measurement measures metabolomics methods nerve degeneration neurofibrillary tangles neuroimaging novel diagnostics outcome measure paper pathogenesis pathology patients peptides perfusion pgrn gene phenotype positron-emission tomography pre-clinical prevent proteins public-private partnership publications publishing research design research personnel resource allocation rest review committee sharing data sleep specificity standardization structure synapses tau proteins tauopathies therapeutic trials tool treatment effect treatment site treatment trial validation visit
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
Organization: Northern California Institute/Res/Edu, United States, California, SAN FRANCISCO
Principal Investigators (PI): Weiner Michael W, US
 
Project Categories:
Natural Sciences
 
Other Information:
Fiscal Year: 2004
Project Start Date: 30 September 2004
Project End Date: 31 July 2021
Project program: Research Program--Cooperative Agreements
 
Project Funding Information:
Funding Mechanism: Non-SBIR/STTR RPGs
Year Funding Organization Total Funding, $
2017 NIH - National Institute On Aging $14,780,250
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Title FY Funding
There are no results for this project in database.
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Project Title Organization FY Funding
Alzheimer'S Disease Neuroimaging InitiativeNorthern California Institute/Res/Edu2017$14,780,250
Alzheimer'S Disease Neuroimaging InitiativeNorthern California Institute/Res/Edu2017$946,418
Alzheimer'S Disease Neuroimaging InitiativeNorthern California Institute/Res/Edu2016$8,000,000
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Title Journal Year Country Rel
Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage 2017 united states
Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements. Hum Brain Mapp 2017 united states
Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology 2017 united states
The cerebellum shrinks faster than normal ageing in Alzheimer's disease but not in mild cognitive impairment. Hum Brain Mapp 2017 united states
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement 2017 united states
Identifying Associations Between Brain Imaging Phenotypes and Genetic Factors via A Novel Structured SCCA Approach. Inf Process Med Imaging 2017 germany
Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. J Parkinsons Dis 2017 netherlands
NETWORK-BASED GENOME WIDE STUDY OF HIPPOCAMPAL IMAGING PHENOTYPE IN ALZHEIMER'S DISEASE TO IDENTIFY FUNCTIONAL INTERACTION MODULES. Proc IEEE Int Conf Acoust Speech Signal Process 2017 united states
Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter? AJNR Am J Neuroradiol 2017 united states
Predicting Interrelated Alzheimer's Disease Outcomes via New Self-Learned Structured Low-Rank Model. Inf Process Med Imaging 2017 germany
Medial temporal lobe subregional morphometry using high resolution MRI in Alzheimer's disease. Neurobiol Aging 2017 united states
The anteroposterior and primary-to-posterior limbic ratios as MRI-derived volumetric markers of Alzheimer's disease. J Neurol Sci 2017 netherlands
Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y) 2017 united states
Detecting genetic association through shortest paths in a bidirected graph. Genet Epidemiol 2017 united states
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol 2016 united states
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 2016 united states
Erratum to: Traumatic brain injury and age at onset of cognitive impairment in older adults. J Neurol 2016 germany
Two-dimensional enrichment analysis for mining high-level imaging genetic associations. Brain Inform 2016 germany
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Title Year
Reducing distortion in magnetic resonance images 2003
Project Title: Alzheimer's disease neuroimaging initiative
Project Number: 5U19AG024904-12
Project web address: Follow on NIH
 
Title Phase Year